**Background**
Major depressive disorder is a prevalent psychiatric condition characterized by persistent low mood and cognitive impairment, often linked to imbalances in monoamine neurotransmitters. The serotonin transporter (SERT) plays a critical role in regulating the synaptic concentration of serotonin, making it a primary target for antidepressant therapy. Beyond mood disorders, emerging research suggests that modulating the serotonergic system may provide neuroprotective benefits in the context of Alzheimer’s disease, particularly regarding the reduction of tau pathology and amyloid-beta plaques. Understanding the Escitalopram biological activity in these contexts is essential for developing therapeutic strategies that address both psychiatric and cognitive decline. Therefore, we will introduce a selective serotonin reuptake inhibitor – Escitalopram.
**Definition**
Escitalopram is the S-enantiomer of racemic citalopram and acts as a selective serotonin reuptake inhibitor (SSRI) with a high binding affinity (Ki = 0.89 nM).
**In Vitro and In Vivo Studies**
According to the Escitalopram technical information, this compound exhibits approximately 30-fold higher binding affinity than its R(-)-enantiomer and shows high selectivity over both the dopamine transporter (DAT) and norepinephrine transporter (NET). In vitro studies using COS-7 cells expressing the wild-type human SERT site S2 demonstrated that Escitalopram (S-1) possesses an IC50 of 4.6 μM for allosteric modulation, assessed by the inhibition of [3H]citalopram dissociation.
The Escitalopram in vivo efficacy has been demonstrated in several animal models. In male Sprague-Dawley rats, administration of Escitalopram (10 mg/kg; i.p.; daily for 28 days) was found to ameliorate cognitive impairments and selectively attenuate the accumulation of phosphorylated tau in the hippocampus of stressed rats, while also alleviating HPA axis hyperactivity. Furthermore, in APP-PS1 hemizygous female mice, chronic administration via drinking water for four months significantly reduced hippocampal plaque load by 28.7% at a dose of 2.5 mg/day and by 34.4% at 5 mg/day compared to controls. In conclusion, Escitalopram is a potent SSRI that holds significant potential for the research of major depression and the mitigation of Alzheimer’s disease-like pathologies.
Keywords
Escitalopram, 128196-01-0, (S)-Citalopram, (S)-(+)-Citalopram, Serotonin Transporter, 5-HTT, SERT, SLC6A4, S-enantiomer, reuptake, selectivity, antidepressant, depression, cognitive, impairments
References
[1] Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53(16): p. 6112-21.
[2] Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10(1): p. 121-8.
[3] Wu C , et al. Escitalopram alleviates stress-induced Alzheimer’s disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity. Neurobiol Aging. 2018;67:137-147.
[4] Cirrito JR, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95(19):e2666-e2674.